49th week of 2012 patent applcation highlights part 42 |
Patent application number | Title | Published |
20120308457 | Alkali-Carbonate-Based Carbon Dioxide Absorbent Containing Added Sterically Hindered Cyclic Amines, and Method for Removing Carbon Dioxide Removing Using Same - The present invention relates to a carbon dioxide absorbent, and more particularly, to an alkali carbonate-based carbon dioxide absorbent containing added sterically hindered cyclic amines, and to a method for removing carbon dioxide using same. By adding sterically hindered cyclic amines to an alkali carbonate material, the rate of carbon dioxide absorption is increased, renewable energy is reduced, and salt production and phase separation do not occur. | 2012-12-06 |
20120308458 | CO2 ABSORPTION FROM GAS MIXTURES USING AN AQUEOUS SOLUTION OF 4-AMINO-2,2,6,6-TETRAMETHYLPIPERIDINE | 2012-12-06 |
20120308459 | CATALYSTS POSSESSING AN IMPROVED RESISTANCE TO POISONING - The present invention relates generally to the field of catalysts for use in connection with one or more types of emissions control (e.g., emissions control associated with the combustion of one or more types of fossil fuel) and, in particular to catalyst compositions that possess an improved resistance to at least one type of poisoning. In another embodiment, the catalysts of the present invention are designed to be utilized in conjunction with an SCR and possess an improved resistance to phosphorus poisoning. | 2012-12-06 |
20120308460 | Nanocomposite Particle and Process of Preparing the Same - A nanocomposite particle, its use as a catalyst, and a method of making it are disclosed. The nanocomposite particle comprises titanium dioxide nanoparticles, metal oxide nanoparticles, and a surface stabilizer. The metal oxide nanoparticles are formed hydrothermally in the presence of the titanium dioxide nanoparticles. The nanocomposite particle is an effective catalyst support, particularly for DeNO | 2012-12-06 |
20120308461 | Crosslinked Polymer-Carbon Sorbent for Removal of Heavy Metals, Toxic Materials and Carbon Dioxide - A polymer-carbon sorbent for removing carbon dioxide, heavy metals and toxic materials from a flue gas from a combustion process, such as coal-fired power plants, is described. The sorbent comprises a carbonaceous sorbent material and a cured amine-containing polymer, and sulfur. The polymer-carbon sorbents are formed by curing a curable amine-containing polymer in the presence of the carbonaceous sorbent material, sulfur, a cure accelerator and, optionally, a cure activator. A convenient carbonaceous sorbent material is an activated carbon, and a convenient curable amine-containing polymer is an allyl-containing poly(ethyleneimine), having a number average molecular weight between about 1,000 and about 10,000. The polymer-carbon sorbents may contain sulfur in excess of an amount needed to cure the curable amine-containing polymer. Such polymer-carbon sorbents are shown to capture more mercury, in both elemental an ionic forms, compared to activated carbon and adsorb carbon dioxide. | 2012-12-06 |
20120308462 | INERT GAS RECOVERY SYSTEM AND METHOD - The method of recovery and recycling of inert gases, especially noble gases, from processes such as vacuum furnaces and other applications. A first gas stream comprising the inert gas and oxidisable impurities, is supplied to an oxidation column comprising a metal oxide. The impurities in the first gas stream are oxidised in the column in the presence of the metal oxide to form a second gas stream containing carbon dioxide and water, the second gas stream is supplied to a regenerable carbon dioxide removal column; the carbon dioxide is removed from the second gas stream in the column to form a third gas stream. Water is removed from the third gas stream in an absorption column, and the exhausted, purified inert gas is collected from the absorption column for conveying to a process utilising the inert gas. The recovered gas stream is of around 6N purity (99.9999% pure) i.e. having 1 ppm total contaminants. | 2012-12-06 |
20120308463 | METHOD AND APPARATUS TO MINIMIZE AIR-SLURRY SEPARATION DURING GYPSUM SLURRY FLOW - A method and apparatus for providing an evenly mixed additive enhanced gypsum slurry to a web. Calcined gypsum and water are inserted into a mixer through at least one inlet of the mixer. The contents are agitated to form a slurry. The slurry is passed from an outlet of the mixer into a conduit. An additive is introduced into the slurry along a length of the conduit to achieve a flow stream of a slurry/additive mixture. A cross section of the flow stream is expanded in the conduit while not changing direction of the flow stream and a direction of the flow stream is changed while not expanding the cross section of the flow stream and conduit, all prior to the flow steam exiting from an outlet of the conduit. | 2012-12-06 |
20120308464 | METHOD AND DEVICE FOR PRODUCING SHORT-CHAIN HALOGENATED POLYSILANES - A method and a device produce short-chain halogenated polysilanes and/or short-chain halogenated polysilanes and halide-containing silicon by thermolytic decomposition of long-chain halogenated polysilanes. The thermolytic decomposition of long-chain halogenated polysilanes diluted with low-molecular halosilanes is carried out under an atmosphere of halosilanes, thereby ensuring the production of such products at industrial scale in a simple and cost-effective manner. | 2012-12-06 |
20120308465 | METHOD FOR PRODUCING TRICHLOROSILANE BY THERMAL HYDRATION OF TETRACHLOROSILANE - Efficient production of trichorosilane from tetrachlorosilane and hydrogen is effected by reaction at high temperatures over short residence times followed by rapidly cooling the product mixture in a heat exchanger, recovered heat being employed to heat the reactant gases, which are then fed to the reactor in a heated state. | 2012-12-06 |
20120308466 | Process for Producing Ammonia Synthesis Gas - A process for producing ammonia synthesis gas from the reforming of hydrocarbons with steam in a primary reformer ( | 2012-12-06 |
20120308467 | SYSTEM AND METHOD FOR AMMONIA SYNTHESIS - Systems and methods are disclosed herein for synthesizing ammonia using nano-size metal or metal alloy catalyst particles. Hydrogen and nitrogen gases are passed through a system comprising, for example, a bed of magnetite supporting nano-size iron or iron alloy catalyst particles having an optional oxide layer that forms the catalyst. | 2012-12-06 |
20120308468 | METHOD FOR PRODUCING GRAPHENE BY CHEMICAL EXFOLIATION - Disclosed are a method for preparing pure graphene using chemical bonding between graphite oxide and metal oxide nanoparticles, and graphene and nanoparticles having a quasi metal oxide-graphene core-shell prepared therefrom. | 2012-12-06 |
20120308469 | CARBON DIOXIDE-ABSORBING SOLUTION AND METHOD OF RECOVERING CARBON DIOXIDE - A method of recovering carbon dioxide, including bringing gas to be processed containing carbon dioxide (CO | 2012-12-06 |
20120308470 | METHOD OF PREPARING CARBON NANOTUBES AND CATALYST FOR PRODUCING CARBON NANOTUBES - A method for preparing carbon nanotubes including attaching a catalyst consisting of a compound in which a transition metal element of Group 8, 9 or 10 is coordinated to a nitrogen-containing dendrimer compound having at least one nitrogen atom, to which a metal element may be coordinated, on a surface of a substrate, and thermally decomposing a carbon compound in the vicinity of the substrate while supplying the carbon compound on the surface of the substrate to which the catalyst is attached. The catalyst for producing the carbon nanotubes is a compound in which a transition metal element of Group 8, 9 or 10 is coordinated to a nitrogen-containing dendrimer compound having at least one nitrogen atom to which a metal element may be coordinated. | 2012-12-06 |
20120308471 | SELECTIVE ETCHING OF SINGLE WALLED CARBON NANOTUBES - Described is a method for the selective etching of single walled carbon nanotubes with CO | 2012-12-06 |
20120308472 | High Porosity/Low Permeability Graphite Bodies And Process For The Production Thereof - A method of forming a graphitic carbon body employs compression and resistance heating of a stock blend of a carbon material and a binder material. During molding of the body, resistance heating is accompanied by application of mechanical pressure to increase the density and carbonization of the resulting preform body. The preform can then be subjected to a graphitization temperature to form a graphite article. | 2012-12-06 |
20120308473 | METHOD AND APPARATUS FOR ADJUSTING THE CONCENTRATION OF ACIDS OR LYES - A method for adjusting a concentration of an acid or lye includes charging a medium for adjusting the concentration of the acid or lye into a supply conduit of the acid or lye so as to provide a combined stream. The combined stream is supplied through an inlet to a mixing chamber such that the combined stream is deflected upon entering the mixing chamber. The combined stream is mixed in the mixing chamber. The combined stream is discharged through an outlet of the mixing chamber such that the combined stream is again deflected upon being discharged from the mixing chamber. | 2012-12-06 |
20120308474 | Process for The Production of Sulfur from Sulfur Dioxide with Tail Gas Recycle - The reduction of the gas stream containing sulfur dioxide to elemental sulfur is carried out by reacting a reducing gas, such as natural gas, methanol or a mixture of hydrogen and carbon monoxide, with recycled sulfur and recycled tail gas to produce a stream containing hydrogen sulfide that may be reacted with the gas stream that contains sulfur dioxide. Gas streams with a molar concentration of sulfur dioxide from 1 to 100% may be processed to achieve nearly 100% sulfur recovery efficiency. | 2012-12-06 |
20120308475 | Oxygen Storage and Generation Using an Oxygen Generating Liquid - Provided are methods and devices for storing and generating oxygen from a low temperature oxygen generating liquid. The oxygen storage method may use lithium chlorate plus water to store oxygen wherein all solids that may be present enter solution for delivery as a liquid to a reaction vessel. The oxygen production method may be a batch process with steps to heat the liquid, boil out the water, thermally decompose the lithium chlorate and then rinse out the remaining product. The apparatus for oxygen generation may use multiple reaction vessels operating sequentially to produce a continuous flow of oxygen with a rinse step in a separate area from the heat application area to remove end product solid. The device for oxygen storage includes a storage vessel and is configured to heat the oxygen generating liquid using waste heat present in the rinse liquid. | 2012-12-06 |
20120308476 | METHODS OF FORMING METAL OXIDE NANOSTRUCTURES, AND NANOSTRUCTURES THEREOF - A method of forming a metal oxide nanostructure comprises disposing a chelated oligomeric metal oxide precursor on a solvent-soluble template to form a first structure comprising a deformable chelated oligomeric metal oxide precursor layer; setting the deformable chelated oligomeric metal oxide precursor layer to form a second structure comprising a set metal oxide precursor layer; dissolving the solvent-soluble template with a solvent to form a third structure comprising the set metal oxide precursor layer; and thermally treating the third structure to form the metal oxide nanostructure. | 2012-12-06 |
20120308477 | BRIEF RADIOIMMUNOTHERAPY - The present invention relates to a method of treating a subject having a cancer in a body cavity characterized in that it comprises the steps of:
| 2012-12-06 |
20120308478 | ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6) - The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer. | 2012-12-06 |
20120308479 | Brain Endothelial Cell Expression Patterns - To gain a better understanding of brain tumor angiogenesis, new techniques for isolating brain endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from brain ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed genes that were specifically elevated in tumor-associated brain endothelium. These results confirm that neoplastic and normal endothelium in human brains are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future. | 2012-12-06 |
20120308480 | HUMANIZED ANTIBODIES AGAINST TL1A - Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function. | 2012-12-06 |
20120308481 | RADIO-OPAQUE COMPOUNDS, COMPOSITIONS CONTAINING SAME AND METHODS OF THEIR SYNTHESIS AND USE - Radio-opaque biodegradable compositions are formed by modifying terminal groups of synthetic and natural biodegradable polymers such as polylactones with iodinated moieties. The biodegradable property of the compositions renders them suitable for use in medical field such as drug delivery, imaging. Compounds disclosed in this invention exist as neat liquid. Certain compositions disclosed in this invention form hydrophobic iodine rich domains when dissolved in water, such domains provide better contrasting properties as well as ability to dissolve hydrophobic bioactive drugs. Certain iodinated moieties disclosed in the invention are capable of cross linking natural proteins in situ in presence of suitable catalysts and co-catalysts. | 2012-12-06 |
20120308482 | Monkey Homolog of Human Interferon Omega - Cytokine IFNω nucleic acids from the Cynomolgus monkey are useful for expression of IFNω proteins that are functional homologs of human IFNω. The nucleic acids and proteins produced therefrom are useful in screening and safety testing of IFNω, the generation and testing of IFNω modulators and related activities. | 2012-12-06 |
20120308483 | Treatment of Sleep Disturbances - The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients. | 2012-12-06 |
20120308484 | Clonal strains of attenuated vaccinia viruses and methods of use thereof - Clonal strains of vaccinia viruses are provided. Also provided are methods of identifying and isolating attenuated and oncolytic clonal strains from virus preparations. Modified recombinant forms of the clonal strains also are provided. The clonal strains and virus preparations can be used for diagnostic and therapeutic methods, in particular for therapy and diagnosis or monitoring treatment of proliferative disorders, including neoplastic diseases, such as, but are not limited to, solid tumors and blood cancers. | 2012-12-06 |
20120308485 | PROCESS FOR THE PREPARATON OF NOVEL PORPHYRIN DERIVATIVES AND THEIR USE AS PDT AGENTS AND FLUORESCENCE PROBES - The present invention provides novel porphyrin derivatives represented by the general formula 1 and/or pharmaceutically acceptable derivatives thereof as NIR sensitizers for photodynamic therapeutic and diagnostic, biological and industrial applications. These porphyrin derivatives posses absorption (400-700 nm) and emission (600-750 nm) in the regions where biological chromophores do not absorb and hence are ideal candidates for application as NIR PDT agents and fluorescence sensors for medicinal applications in biology. The substituents like hydroxyl and glycolic units on these dyes render them amphiphilicity thereby improving their solubility in the aqueous media and cellular uptake and localization. These dyes show no toxicity in the dark and are highly selective towards tumor cells and stain nucleus very rapidly. Accordingly, these porphyrin derivatives are extremely useful as NIR PDT fluorescence sensors in photodynamic therapeutic and diagnostic, biological and industrial applications. | 2012-12-06 |
20120308486 | Fragrance and/or flavoring compositions containing dioxolanes - The present invention primarily relates to the use of dioxolanes of the following Formula (I) as fragrance and/or flavoring substances, certain perfume and/or flavoring compositions comprising these dioxolanes and corresponding perfumed and/or flavored items. | 2012-12-06 |
20120308487 | Carnallite Preparation and Uses Thereof in Edible Applications - The present invention relates to a Carnallite salt preparation useful in edible products, such as a food, beverage, dietary supplement, oral care, nutraceutical pet food, animal feed, pharmaceutical and other edible products. The Carnallite salt preparation of the invention is without high levels of sodium chloride and notably low in bromide. The Carnallite salt preparation may be a food grade product with dietary acceptable bromide levels. The present invention further relates to edible products comprising the Carnallite salt preparation, such as reduced sodium food products. | 2012-12-06 |
20120308488 | ORAL CARE PRODUCT FOR SENSITIVE ENAMEL CARE - Disclosed are anti-erosion oral care formulations and methods that provide erosion protection while maintaining adequate cleaning performance. The anti-erosion oral care formulations include a mucoadhesive polymer and a zinc compound or salt that becomes more soluble at acidic pH. | 2012-12-06 |
20120308489 | ORAL CARE COMPOSITIONS - Disclosed herein are methods of enhancing the solubility and delivery of one or more active ingredients found in magnolia extract, or a synthetic analogue thereof, in an oral composition. | 2012-12-06 |
20120308490 | METHOD OF OBTAINING A PREPARATION OF BIOLOGICAL ORIGIN FOR ORAL HYGIENE TO PREVENT THE ONSET OF TOOTH DECAY - A method of obtaining a preparation of biological origin for oral hygiene to prevent the onset of tooth decay, comprises steps of fermentation of bacteria in a culture medium, separation of the same and purification of the culture medium in which the bacteria have been cultivated, the step of fermentation of bacteria including a combined addition of starch and cellulose to the culture medium to the final concentration in the culture medium between 0.2 g/l and 2 g/l, and preferably of 0.5 g/l each. | 2012-12-06 |
20120308491 | DENTIFRICE COMPOSITIONS - Described herein are dentifrice compositions comprising a zinc-containing salt and carboxypeptidase, wherein the zinc-containing salt is not sequestered. | 2012-12-06 |
20120308492 | FOAMABLE OIL-WATER EMULSION - The present invention relates to foamable oil-in-water emulsions containing: A) one or more emulsifiers, at least one of which is a non-ionic emulsifier, B) one or more cotensides, C) one or more oils, D) optionally, one or more polar solubilizers, E) optionally, auxiliary and additive substances, F) one or more surfactants, G) water, H) optionally, water-soluble substances, provided that the water content of the emulsion is ≧70% by weight and the concentration of surfactant(s) F) is from 0.01 to less than 10% by weight, each based on the entire emulsion. The invention further relates to a method for producing the oil-water emulsions according to the invention, to foams obtained from these oil-water emulsions, to a method for producing the foams, and to the application of the oil-water emulsions according to the invention and to the foams produced therefrom. | 2012-12-06 |
20120308493 | PAWPAW AND/OR PEACH DERIVED COMPOSITION - There is provided a process for making a composition suitable for topical application comprising the steps of a) heating at least one fruit and/or vegetable pulp to up to a temperature in the range of about 40° C. to 100° C.; b) mixing between 1 and 40% w/w of a mild base with the heated fruit and/or vegetable pulp. There is also provided a fruit and/or vegetable derived composition suitable for topical application prepared by the above process. There is further provided a fruit and/or vegetable derived composition comprising at least one fruit and/or vegetable derived pulp and a mild base, said composition having a pH in the range of about 7.5 to about 9.5. | 2012-12-06 |
20120308494 | NOVEL LINEAR POLYDIMETHYLSILOXANE-POLYETHER COPOLYMERS HAVING AMINO AND/OR QUATERNARY AMMONIUM GROUPS AND USE THEREOF - Linear polydimethylsiloxane-polyether copolymers with amino and/or quaternary ammonium groups, obtainable by the reaction of organopolysiloxanes functionalized with secondary aminoalkyl groups with the reaction products formed from compounds containing epoxy groups and amines, the use thereof and process for preparation thereof. | 2012-12-06 |
20120308495 | PHOTOSTABILIZATION OF COENZYME Q COMPOUNDS WITH ALKOXYCRYLENE COMPOUNDS - A method of reducing photodegradation of a coenzyme Q | 2012-12-06 |
20120308496 | SUN PROTECTION COMPOSITIONS - The invention relates to sun protection compositions for application on the skin, containing special polyurethanes and special sun filter combinations, and to the use of said polyurethanes and sun filter combinations for producing sun protection products. | 2012-12-06 |
20120308497 | NAIL POLISH WITH A CRACK AND COLOR CHANGING EFFECT - A nail polish with a crack and color changing effect includes a polymer, a solvent, a plasticizer, a pigment, a silica and a thermochromic powder. The polymer accounts for 10%-30% of the total weight and contains nitrocellulose and resin. The solvent accounts for 44%-64% of the total weight. The plasticizer accounts for 3%-8% of the total weight. The silica accounts for 8% of the total weight. The pigment accounts for 10%-20% of the total weight. The thermochromic powder accounts for 5% of the total weight. The nail polish with a crack and color changing effect composed by the aforementioned components may generate cracks after being applied and dried and also generate a color changing effect with the changing of the temperature of nails. | 2012-12-06 |
20120308498 | DYEING AND/OR BLEACHING COMPOSITION COMPRISING A POLYCONDENSATE OF ETHYLENE OXIDE AND PROPYLENE OXIDE - The invention relates to a device having one or more compartments, or “kit”, for dyeing keratin fibres, in which a first compartment contains a dye composition free of oxidizing agent, comprising at least one hair dye and at least one polycondensate of ethylene oxide and propylene oxide consisting of polyethylene glycol and polypropylene glycol blocks, and optionally a second compartment contains an oxidizing composition. | 2012-12-06 |
20120308499 | COSMETIC CARE OR MAKEUP COMPOSITION CONTAINING POWDERS AND MANUFACTORING PROCESS - The invention relates to a solid cosmetic composition, in the form of a loose or compact powder, comprising:
| 2012-12-06 |
20120308500 | LIP STICK - Disclosed is an anhydrous lipstick comprising a combination of active ingredients comprising | 2012-12-06 |
20120308501 | AQUEOUS ANTIPERSPIRANT/DEODORANT COMPOSITION - An aqueous antiperspirant/deodorant composition comprising: (a) at least one active chosen from an antiperspirant active and a deodorant active, (b) a mixture comprising at least one basic compound chosen from a basic amide and a basic amine and a counterpart material for the basic amide and/or basic amine, and (c) at least 10 weight % water. Also, a method of manufacturing the composition. | 2012-12-06 |
20120308502 | Personal Care Composition Comprising a Surfactant-Rich Gel Network - The present application relates to a process for preparing a personal care composition by combining a fatty amphiphile above its melt temperature and a surfactant in a weight ratio from 0.1:1 to 0.99:1 to form a gel network premix contacting the gel network premix with a shearing device, cooling the gel network premix to a temperature below the melt temperature of the fatty amphiphile and adding the cooled premix to personal care components to form the personal care composition. | 2012-12-06 |
20120308503 | COSMETIC COMPOSITION CONTAINING POLYGLYCEROL PARTIAL ESTER - The present invention relates to cosmetic compositions containing polyglycerol partial esters of linear, unsubstituted carboxylic acids with the provisos that the polyglycerol obtained by hydrolysis or alcoholysis of the polyglycerol partial ester comprises an average degree of polymerization of from 2 to 8 and the polydispersity index of said polyglycerol is greater than 0.75. The present invention also relates to the use of aforementioned polyglycerol esters for the production of and use in cosmetic compositions. | 2012-12-06 |
20120308504 | COSMETIC COMPOSITION COMPRISING OIL-IN-WATER EMULSION AND MASCARA FOR EYELASHES - The present invention describes a cosmetic composition comprising an oil-in-water emulsion for application on keratinic materials, of long lasting duration, that presents an ideal drying time and a crystalline network film structure that is more resistant, homogenous and flexible, allowing the application of the end product on the hairs in a cohesive, non-crumbling and uniform manner, without the formation of lumps. The cosmetic composition of long lasting duration, object of the present invention, comprises: a film forming complex comprising at least one hydrosoluble or hydrodispersible film forming agent and at least one liposoluble or lipodispersible film forming agent; a shine and performance improvement promoting complex of the end product; and a cosmetically acceptable carrier. The present invention also refers to massacres for eyelashes or hairs comprising the aforesaid cosmetic composition. | 2012-12-06 |
20120308505 | Clear Hair Care Composition Comprising Base Oil and Hydrophilic Component - Disclosed is a non-aqueous clear hair care composition comprising by weight: from about 61% to about 99.9% of a base oil consisting of: an isoparaffin, a mineral oil, a volatile silicone compound, and mixtures thereof; from about 0.0005% to about 0.1% of an hydrophilic material; from about 0.035% to about 15% of a liquid fatty alcohol having 10 carbon atoms or more; wherein the weight ratio of the hydrophilic material to the liquid fatty alcohol is from about 1:70 to about 1:800. By the use of liquid fatty alcohol, hydrophilic materials are dissolved in the base oil and the composition has a clear product appearance. | 2012-12-06 |
20120308506 | Clear Hair Care Composition Comprising Base Oil and Silicone - Disclosed is a non-aqueous hair care composition comprising by weight: (a) from about 65% to about 99.9% of a base oil consisting of: an volatile isoparaffin; a first non-volatile mineral oil having a lower viscosity and density; and a second non-volatile mineral oil having a higher viscosity and density; and (b) from about 0.1% to about 15% of a non-volatile silicone conditioning agent. | 2012-12-06 |
20120308507 | Odor-Inhibiting Mixtures for Incontinence Articles - Odor-inhibiting mixtures comprising water-absorbing polymer particles and spherical activated carbon for use in incontinence articles. | 2012-12-06 |
20120308508 | MICROGEL COMPOSITIONS - This invention relates to microgel compositions, and in particular, to gel compositions formed by binding a plurality of individual microgel particles together. The present invention also relates to processes for the preparation of these compositions and their use for particular applications, especially medical applications such as the repair of damaged, degenerated or inappropriately formed load-bearing tissue (such as, for example, intervertebral discs). | 2012-12-06 |
20120308509 | Method and Composition for In Situ Formation of an Artificial Blockage to Control Blood Loss - Two siloxane-based mixtures combine to form a soft or semi-solid matrix for forming an artificial blockage to control bleeding, particularly moderate to severe bleeding. The first component includes a homogeneous mixture or solution that includes a polymeric matrix, a surfactant, filler(s) and metal compound(s). The second component includes a homogeneous mixture or solution that includes a polymer(s), a filler(s), a surfactant, and hydrogen peroxide. The combination of the two components is carried out with adequate mixing using mechanical and micro-kinetic mixing mechanisms and can be performed in a field-ready delivery device. | 2012-12-06 |
20120308510 | METHOD, COMPOSITION, AND ARTICLES FOR IMPROVING JOINT LUBRICATION - Articles for increasing lubrication of a joint are described herein. The articles include resorbable, biocompatible particles having a glass transition temperature within a joint of less than about 37° C. and capable of increasing fluid movement within the joint compared to synovial fluid, viscosupplemental fluid, or combinations thereof. A composition for increasing lubrication of a joint is also disclosed. The composition includes the resorbable, biocompatible particles and a carrier fluid. Methods of lubricating a joint and treating disease affecting the joint such as osteoarthritis are also described herein. The methods include introducing the resorbable, biocompatible particles into a joint. | 2012-12-06 |
20120308511 | Co-Therapy for Diabetic Conditions - Methods of treating diseases such as diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof. Drug products including a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof, in combination are also disclosed. | 2012-12-06 |
20120308512 | Bio-Polymer Air Effector Delivery Systems - The present invention comprises a bio-polymer based solid for the sustained release of an active agent into the air consisting of:
| 2012-12-06 |
20120308513 | PROMISCUOUS HER-2/NEU CD4 T CELL EPITOPES - The present invention relates to the discovery of novel T cell epitopes of the human HER-2/Neu protein that is promiscuous for at least 25 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such a epitope and a heterologous polypeptide. Further disclosed herein is the use of the epitopes or their fusion peptides, and compositions containing the epitopes or their fusion peptides. | 2012-12-06 |
20120308514 | HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING - Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention. | 2012-12-06 |
20120308515 | USE OF GILZ PROTEIN EXPRESSED IN DENDRITIC CELLS TO MODULATE AN ANTIGEN-SPECIFIC IMMUNE RESPONSE - A pharmaceutical composition comprising at least dendritic cells modified with a molecule selected from the group consisting of: a GILZ protein or a functional fragment of at least 5 consecutive amino acids of said protein; a small interfering RNA (siRNA) targeting the GILZ transcript or an antisense oligodeoxynucleotide complementary to said transcript; and a recombinant expression vector containing a polynucleotide encoding said GILZ protein, said fragment, said siRNA or said antisense oligodeoxynucleotide complementary to said transcript and a pharmaceutically acceptable carrier. In addition, a method for treatment of autoimmune diseases, inflammatory diseases, allergies, transplant rejection and graft-versus-host disease, cancers or pathogenic microorganism infections by administering an effective amount of said pharmaceutical composition to a subject in need thereof. | 2012-12-06 |
20120308516 | USE OF METALLOCENE COMPOUNDS FOR CANCER TREATMENT - Metallocene compounds and pharmaceutical compositions containing these metallocene compounds are disclosed and described. Methods of treating cancer employing such metallocene compounds and pharmaceutical compositions also are provided. | 2012-12-06 |
20120308517 | COMPOSITIONS FOR THE TREATMENT OF INFECTIOUS AND TUMOURAL DISEASES - The present invention relates to the use of compositions comprising a type III interferon and oncostatin M and to the use of said compositions for the treatment and prevention of infectious and neoplastic diseases. | 2012-12-06 |
20120308518 | METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF STROKE AND RELATED DISEASES AND DISORDERS - Cells present in adipose tissue are used to stroke and stroke related diseases and disorders in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit. | 2012-12-06 |
20120308519 | Anti-Arenaviral Compounds - Described herein are 4-methyl-piperazine-1-carbothioic acid amide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by hemorrhagic fever viruses, such as Arenaviruses. | 2012-12-06 |
20120308520 | CRYSTAL OF RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION, THREE-DIMENSIONAL STRUCTURE AND USES THEREOF - This invention provides crystalline recombinant interferon (rSIFN-co) having (i) the same amino acid sequence as that of human consensus interferon, and (ii) altered three-dimensional structure as compared to IFN-α2b. The interferon of the present invention exhibits enhanced biological activities. The present invention also provides a structural model of said interferon useful for drug screening and/or drug design, and mimetics of said interferon. | 2012-12-06 |
20120308521 | Compositions and Methods for Treatment of Cancer Using Tissue-Specific Oncolytic Adenoviruses - The present invention includes the use of a nucleic acid sequence encoding an shRNA to target RNA interference against a cellular factor where such use can enhance oncolytic adenovius replication. The nucleic acid sequence encoding an shRNA can be introduced into an oncolytic adenovius construct via a recombination event, and such nucleic acid sequence encoding an shRNA can reside in either the E1 region or Fiber region of the oncolytic adenovius construct. In particular, the oncolytic adenovius construct optionally include a prostate specific promoter or prostate specific enhancer for issue specific expression in prostate cancer cells. The oncolytic adenovius constructs of the invention provides utility for the treatment of cancers, in particular prostate cancer. | 2012-12-06 |
20120308522 | Therapeutic Use of Growth Factor, and Delivery Device, Especially for the Treatment of Intimal Hyperplasia - Vascular endothelial growth factor (VEGF) has utility in the treatment of intimal hyperplasia, hypertension and atherosclerosis, and of conditions susceptible to treatment with agents that produce nitric oxide or prostacyclin. Instead of VEGF, an equivalent agent such as an agonist of VEGF receptors may be given, as may nucleic acid encoding such an agonist. The agent may successfully be administered via the adventitial surface of a blood vessel, e.g. using a device which defines a reservoir between the body wall and the vessel's adventitial surface, the reservoir being at least part-filled by a pharmaceutical formulation containing the agent to be delivered. | 2012-12-06 |
20120308523 | Method for Reducing Gastro-Intestinal Inflammation Using Bifidobacterium Animalis Bacteria or a Fermented Dairy Product Comprising Such Bacteria - The present invention relates to a method for the prevention, treatment and reduction of gastro-intestinal inflammation in a subject by administering a specific | 2012-12-06 |
20120308524 | COMPOSITION FOR USE IN THE THERAPY OF LACTOSE INTOLERANCE OR CONDITIONS ARISING FROM LACTASE DEFICIENCY - The invention provides a composition for use in therapy of lactose intolerance or conditions arising from lactase deficiency, wherein the composition is a non-dairy solid dosage form comprising:
| 2012-12-06 |
20120308525 | NUTRITIONAL COMPOSITIONS INCLUDING A HIGH PROTEIN COMPONENT AND EXOGENOUS NUCLEOTIDES - Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including a high protein component and one or more exogenous nucleotides. The nutritional compositions can be specifically used to accelerate and improve wound healing in a mammal. | 2012-12-06 |
20120308526 | Sonic Low Pressure Spray Drying - This invention provides methods of spray drying pharmaceutical powders from a vibrating nozzle at low pressures. The method can effectively spray dry thick or viscous solutions or suspensions to provide small uniform particles. The invention includes dry particle compositions prepared by methods of low pressure spraying from vibrating nozzles. | 2012-12-06 |
20120308527 | PREVENTION OF OPPORTUNISTIC INFECTIONS IN IMMUNE-COMPRISED SUBJECTS - This invention relates to a composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals comprising a probiotic | 2012-12-06 |
20120308528 | Methods and Compositions for Gene Inactivation - Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. | 2012-12-06 |
20120308529 | COMPOSITIONS COMPRISING ADIPOSE STEM CELLS - The present invention relates to adipose stem cell compositions, methods for making said compositions, kits comprising said compositions and uses of said compositions in the therapy of diseases. | 2012-12-06 |
20120308530 | Materials Composition and Methods to Control Neural Progenitor and Stem Cell Attachment, Proliferation and Guide Cell Differentiation - This invention disclosure provides culture surface compositions and methods that control the NPCs and NSCs, and/or MSCs to either largely maintain their phenotypes, or differentiate on these culture surfaces in guided lineage. The culture surface composition can be constructed to contain either OH functional groups, or —NH | 2012-12-06 |
20120308531 | Expansion of Stem Cells in Hollow Fiber Bioreactors - The invention is directed to producing large numbers of cells using hollow fiber bioreactor technology. The cells are non-embryonic stem, non-germ cells that can be characterized by one or more of the following: extended replication in culture and markers of extended replication, such as telomerase, markers of pluripotentiality, and broad differentiation potential, without being transformed. | 2012-12-06 |
20120308532 | COMPOSITION FOR THE TREATMENT OF A BONE FRACTURE - There is disclosed a composition formed by a reaction of at least one component A and at least one component B, wherein component A is selected from the group consisting of a compound comprising at least two thiol-groups and a disulfide derivative of a compound comprising at least two thiol groups, and wherein component B is a compound comprising at least two vinyl groups, for the manufacture of an implant for the treatment of a bone fracture. Advantages include that the adhesive patch formed by the composition will be solid in body fluid upon curing and will exhibit excellent mechanical strength. Advantages include that the composition is biocompatible, the material can be applied in small and inaccessible areas, the process requires less surgeon training, it solves drawback with open surgery, and it is possible to use cost effective materials and methods in the process. | 2012-12-06 |
20120308533 | ADIPOCYTE SHEET, THREE-DIMENSIONAL STRUCTURE THEREOF, AND METHOD FOR PRODUCING THE SAME - The present invention aims to provide an artificial tissue that can efficiently reproduce myocardial tissue function and that can be used in an actual implantation and produced by culturing. The present invention relates to a graft material for treating myocardial disease, the graft material including a cell sheet containing adipocytes. | 2012-12-06 |
20120308534 | NEURAL PROGENITOR CELL POPULATIONS - This invention provides populations of neural progenitor cells, differentiated neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural progenitor population. The progenitors can be further differentiated in culture into a variety of different neural phenotypes, including dopaminergic neurons. The differentiated cell populations or the neural progenitors can be generated in large quantities for use in drug screening and the treatment of neurological disorders. | 2012-12-06 |
20120308535 | Pharmaceutical Composition Containing Expanded Adult Stem Cells and Methods of Using Same for Treatment - A method for the expansion of adult stem cells from blood, particularly but not only peripheral blood, involves removing adult stem cells from blood of a mammal, immediately expanding the stem cells via in-vitro treatment with MCSF (Macrophage Colony Stimulating Factor) at a concentration of about 8-15 nM, and purifying the expanded stem cells. Compositions and methods of using the expanded adult stem cells are also described. | 2012-12-06 |
20120308536 | METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER - Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of cells comprising disaggregated adipose-derived stem cells, mixing the concentrated population of adipose-derived cells comprising disaggregated adipose-derived cells with a portion of unprocessed, intact, non-disaggregated adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed. | 2012-12-06 |
20120308537 | Use Of Collagen Type VII For Maintaining And Re-Inducing Osteogenic Abilities Of Mesenchymal Stem Cells - This invention provides methods of inducing and maintaining osteogenic potential in mesenchymal stem cells and compositions for doing the same. The compositions this invention comprise collagen 7 (C7), the NC1 domain of C7, or the 27 kD fragment of C7. Also provided are methods for treating bone diseases and correcting bone defects by applying compositions of this invention or by first priming ex vivo mesenchymal stem cells with compositions of this invention and then applying the primed mesenchymal stem cells to the patient. The invention further provides a mesenchymal stem cell osteogenesis induction kit. | 2012-12-06 |
20120308538 | PREVENTING SPOILAGE IN ALCOHOL FERMENTATIONS - The invention relates to the prevention of bacterial spoilage during fermentation. In particular it relates to the prevention of beer and wine spoilage, but also the spoilage of bioethanol or biogas. This is accomplished by modifying the fermentation yeast to produce an antimicrobial peptide known as a defensin. One such defensin is the human β-defensin-3 (HBD-3) although many others can be used. | 2012-12-06 |
20120308539 | LACTIC ACID BACTERIA HAVING ACTION OF LOWERING BLOOD URIC ACID LEVEL - Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, | 2012-12-06 |
20120308540 | Modified factor IX polypeptides and uses thereof - Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 2012-12-06 |
20120308541 | PHARMACEUTICAL COMPOSITION FOR TREATING THE GASTROINTESTINAL TRACT - Provided are pharmaceutical compositions for the treatment or prophylaxis of the gastrointestinal tract. One of the pharmaceutical composition includes co-particles of an adsorbent, and one or more carbohydrates. This pharmaceutical composition may be used, for example, in the treatment or prophylaxis of diarrhea, for adsorbing digestive tract microorganisms, for enhancing weight gain, or for enhancing milk production in a mammal. Another pharmaceutical composition can include one or more enzymes and a pH buffer system, wherein the pH buffer system causes an alkalinization of at least a portion of a gastrointestinal tract. This pharmaceutical composition may be used, for example, for increasing milk production in a mammal. | 2012-12-06 |
20120308542 | Method for Ameliorating or Preventing Arrhythmic Risk Associated with Cardiomyopathy by Improving Conduction Velocity - A method for reducing arrhythmic risk associated with cardiomyopathy by improving conduction velocity, includes administering a composition containing NAD | 2012-12-06 |
20120308543 | Lipase Variants for Pharmaceutical Use - The pharmaceutical use of lipases related to the | 2012-12-06 |
20120308544 | Substances and Methods for the Treatment of Lysosmal Storage Diseases - The present invention relates to a chimeric molecule comprising (i) a targeting moiety that binds to heparin or heparan sulfate proteoglycans, (ii) a lysosomal peptide or protein, (iii) wherein the targeting moiety is a neurotrophic growth factor and/or, wherein the targeting moiety comprises one of the following consensus sequences BBXB, BXBB, BBXXB, BXXBB, BBXXXB or BXXXBB and wherein B represents an arginine, lysine or histidine amino acid and X represents any amino acid, (iii) with the proviso that the targeting moiety is at least thirteen amino acids long. | 2012-12-06 |
20120308545 | Crystallized Oxalate Decarboxylase and Methods of Use - Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals. | 2012-12-06 |
20120308546 | POLYMERS FOR REVERSING HEPARIN-BASED ANTICOAGULATION - Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules. | 2012-12-06 |
20120308547 | COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS - One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided. | 2012-12-06 |
20120308548 | METHIONINE GAMMA LYASE-2-AMINOBUTYRATE DEAMINASE (MEGL-2ABD) AND THERAPEUTIC USES THEREOF - The invention relates to a methionine gamma lyase-2-aminobutyrate deaminase (MEGL-2ABD) enzyme and provides an isotopic assay for quantitatively measuring activity of the enzyme. The MEGL-2ABD is a therapeutic target for cancer, particularly in cancer stem cells and their lineages. The invention additionally provides a protein, MEGL-2ABD (SEQ ID NO:2), compositions/formulations containing this protein, and methods/assays for using this protein in therapeutic applications allowing progress toward prevention, diagnosis, treatment, and cure of cancer. | 2012-12-06 |
20120308549 | PROCESS FOR PRODUCTION AND PURIFICATION OF RECOMBINANT LYSOSOMAL ALPHA-MANNOSIDASE - The present invention relates to a process for purification of recombinant alpha-mannosidase, a process for production of alpha-mannosidase, a composition comprising alpha-mannosidase, use of the composition as a medicament, use as a medicament for the treatment of alpha-mannosidosis and a method of treating alpha-mannosidosis and/or alleviating the symptoms of alpha-mannosidosis. | 2012-12-06 |
20120308550 | Method of Using Fish Plasma Components to Promote Functional Recovery in the Mammialian CNS - A method includes applying thrombin and salmon fibrinogen to injured motor neurons at a central nervous system injury site, thereby enhancing repair and functional recovery of the injured motor neurons, such as by injecting or spraying thrombin and salmon fibrinogen to form a fibrin clot, or by applying a composition including thrombin and salmon fibrinogen. A method of promoting the functional recovery of a patient who has suffered a central nervous system injury includes this method. A composition including thrombin and salmon fibrinogen is adapted to be applied to injured motor neurons at a central nervous system injury site, thereby enhancing repair and functional recovery of the injured motor neurons. | 2012-12-06 |
20120308551 | Protease screening methods and proteases identified thereby - Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases. | 2012-12-06 |
20120308552 | Hemostatic bio-material composition and method - The present invention relates to a haemostatic bio-material composition and method for achieving hemostasis. The method for providing hemostasis generally comprises: supplying a dry potassium phosphate based hemostat mixture comprising: monobasic potassium phosphate, a metal oxide, and a tertiary calcium phosphate, wherein the weight percent ratio of monobasic potassium phosphate to metal oxide is between about 3:1 and 1:1; mixing the dry potassium phosphate based hemostat mixture with an aqueous solution forming an activated hemostat slurry; applying an hemostasis-promoting amount of the activated potassium phosphate based hemostat slurry to a site of bleeding; wherein the site of bleeding is in, on, or proximate to bone. | 2012-12-06 |
20120308553 | ORAL MEDICATION FOR THE TREATMENT OF HEMORRHOIDS AND METHOD OF USE - A natural supplement in the form of an orally ingested tablet for treatment of hemorrhoids. Bromelain and Psyllium (e.g., Psyllium husk powder) are the primary active ingredients in the natural supplement tablet. Optionally, Witch Hazel, in the form of Witch Hazel leaf, for example, may be added to the composition. Secondary ingredients include Dicalcium Phosphate, Cellulose, Croscarmellose Sodium, Stearic Acid and Silicon Dioxide. Based on case studies the natural supplement outperforms over-the-counter and prescribed hemorrhoid medications. | 2012-12-06 |
20120308554 | VEGF-D/VEGFR2/3-MEDIATED REGULATION OF DENDRITES - The present invention relates to methods for modulating, i.e. increasing or decreasing, the length and/or the complexity of the dendrites of a neuronal cell by influencing the amount of vascular endothelial growth factor D (VEGFD)-related signaling. The present invention further relates to methods for treating age- and/or disease-related cognitive dysfunctions, or for impairing the memory of a subject. Finally, the present invention relates to recombinant VEGFD (rVEGFD) for use in the treatment of age- and/or disease-related cognitive dysfunctions. | 2012-12-06 |
20120308555 | METHODS AND REAGENTS FOR CREATING MONOCLONAL ANTIBODIES - In some embodiments, the invention relates to methods for creating a monoclonal antibody that specifically binds to antigen. The method may start from a polyclonal population of antibodies such as a non-specific polyclonal population or a polyclonal population of antibodies that specifically bind to the antigen. The method includes obtaining nucleic acid molecules encoding heavy and light immunoglobulin chains (or variable regions thereof) of multiple immunoglobulins from an animal; obtaining mass spectra information of peptide fragments of a population of polyclonal immunoglobulins that specifically bind to an antigen of choice; comparing and/or correlating the mass spectra information of the peptide fragments of the polyclonal immunoglobulins with predicted mass spectra information of predicted amino acid sequences encoded by the nucleic acid molecules, and then assembling the heavy and light chains to create an antibody (or variable region thereof) that specifically binds to the antigen. | 2012-12-06 |
20120308556 | PROCESSED ECM MATERIALS WITH ENHANCED COMPONENT PROFILES - Described are medical graft materials and devices having improved properties relating to their component profiles. | 2012-12-06 |